uric acid has been researched along with Cachexia in 3 studies
Uric Acid: An oxidation product, via XANTHINE OXIDASE, of oxypurines such as XANTHINE and HYPOXANTHINE. It is the final oxidation product of purine catabolism in humans and primates, whereas in most other mammals URATE OXIDASE further oxidizes it to ALLANTOIN.
uric acid : An oxopurine that is the final oxidation product of purine metabolism.
6-hydroxy-1H-purine-2,8(7H,9H)-dione : A tautomer of uric acid having oxo groups at C-2 and C-8 and a hydroxy group at C-6.
7,9-dihydro-1H-purine-2,6,8(3H)-trione : An oxopurine in which the purine ring is substituted by oxo groups at positions 2, 6, and 8.
Cachexia: General ill health, malnutrition, and weight loss, usually associated with chronic disease.
| Excerpt | Relevance | Reference |
|---|---|---|
| " We aimed to study the relationship between serum uric acid levels and leg vascular resistance in patients with CHF with and without cachexia and in healthy control subjects." | 7.71 | Uric acid in cachectic and noncachectic patients with chronic heart failure: relationship to leg vascular resistance. ( Anker, SD; Bolger, AP; Coats, AJ; Davos, CH; Doehner, W; Florea, VG; Rauchhaus, M; Sharma, R, 2001) |
| " We aimed to study the relationship between serum uric acid levels and leg vascular resistance in patients with CHF with and without cachexia and in healthy control subjects." | 3.71 | Uric acid in cachectic and noncachectic patients with chronic heart failure: relationship to leg vascular resistance. ( Anker, SD; Bolger, AP; Coats, AJ; Davos, CH; Doehner, W; Florea, VG; Rauchhaus, M; Sharma, R, 2001) |
| "Cachexia is a common co-morbidity in cancer occurring in up to 80% of patients depending on the type of cancer." | 1.38 | Inhibition of xanthine oxidase reduces wasting and improves outcome in a rat model of cancer cachexia. ( Adams, V; Anker, SD; Argiles, JM; Doehner, W; Hartman, K; Köhrle, J; Möller, N; Palus, S; Ruis, SB; Springer, J; Tschirner, A; von Haehling, S; Wirth, EK, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lainscak, M | 1 |
| von Haehling, S | 2 |
| Anker, SD | 3 |
| Springer, J | 1 |
| Tschirner, A | 1 |
| Hartman, K | 1 |
| Palus, S | 1 |
| Wirth, EK | 1 |
| Ruis, SB | 1 |
| Möller, N | 1 |
| Argiles, JM | 1 |
| Köhrle, J | 1 |
| Adams, V | 1 |
| Doehner, W | 2 |
| Rauchhaus, M | 1 |
| Florea, VG | 1 |
| Sharma, R | 1 |
| Bolger, AP | 1 |
| Davos, CH | 1 |
| Coats, AJ | 1 |
3 other studies available for uric acid and Cachexia
| Article | Year |
|---|---|
Natriuretic peptides and other biomarkers in chronic heart failure: from BNP, NT-proBNP, and MR-proANP to routine biochemical markers.
Topics: Anemia; Biomarkers; Cachexia; Cystatin C; Growth Differentiation Factor 15; Heart Failure; Humans; H | 2009 |
Inhibition of xanthine oxidase reduces wasting and improves outcome in a rat model of cancer cachexia.
Topics: Allopurinol; Animals; Body Composition; Body Weight; Cachexia; Caspase 3; Enzyme Inhibitors; Male; N | 2012 |
Uric acid in cachectic and noncachectic patients with chronic heart failure: relationship to leg vascular resistance.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers; Blood Flow Velocity; Blood Pressure; Cachexia; Confidenc | 2001 |